Critical appraisal of belinostat in the management of T-cell lymphoma – patient considerations

Andrew Bodiford,1 Mahsa S Talbott,1 Nishitha M Reddy,2 1Department of Pharmacy, 2Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA Abstract: The histone deacetylase inhibitor (HDACi), belinostat, is an emerging and novel therapeutic...

Full description

Saved in:
Bibliographic Details
Main Authors: Bodiford A, Talbott MS, Reddy NM
Format: article
Language:EN
Published: Dove Medical Press 2015
Subjects:
Online Access:https://doaj.org/article/7f9b2bb7038a46f3b3e17cfcefd11a9f
Tags: Add Tag
No Tags, Be the first to tag this record!